F E van Beek1, F Jansen2, L Mak1, B I Lissenberg-Witte3, J Buter4, M R Vergeer5, J Voortman4, P Cuijpers1, C R Leemans6, I M Verdonck-de Leeuw7. 1. Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, van der Boechorststraat 1, 1081 BT Amsterdam, the Netherlands. 2. Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, van der Boechorststraat 1, 1081 BT Amsterdam, the Netherlands; Department of Otolaryngology-Head and Neck Surgery, Amsterdam Public Health Research Institute, AmsterdamUMC location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. 3. Department of Epidemiology and Biostatistics, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. 4. Department of Medical Oncology, AmsterdamUMC location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. 5. Department of Radiation Oncology, AmsterdamUMC location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. 6. Department of Otolaryngology-Head and Neck Surgery, Amsterdam Public Health Research Institute, AmsterdamUMC location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. 7. Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, van der Boechorststraat 1, 1081 BT Amsterdam, the Netherlands; Department of Otolaryngology-Head and Neck Surgery, Amsterdam Public Health Research Institute, AmsterdamUMC location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Electronic address: im.verdonck@amsterdamumc.nl.
Abstract
OBJECTIVES: To identify sociodemographic and clinical factors, health-related quality of life (HRQOL) and head and neck cancer (HNC) symptoms associated with the course of symptoms of anxiety and depression from pretreatment to 24-month follow-up among HNC patients after (chemo)radiation. MATERIALS AND METHODS: Patients (n = 345) completed questionnaires on anxiety and depression (HADS), HRQOL and symptoms (EORTC QLQ-C30/QLQ-H&N35) before treatment, and 6-weeks,3-,6-12-,18-, and 24-months after treatment. Mixed model analyses were used to investigate the course of anxiety and depression from pretreatment to 24-months in relation to factors assessed at baseline, and the course of anxiety and depression from 6- to 24-months, in relation to factors assessed at 6-months. RESULTS: Increased risk for anxiety (HADS-anxiety > 7) was 28.7% among patients before treatment, which declined to 10.0% at 24-months. Increased risk for depression (HADS-depression > 7) was 15.1% before treatment, 18.2% at 3-months, 7.2% at 12-months and 16.0% at 24-months. Factors assessed at baseline which were significantly associated with the course of anxiety were age, pain, problems with social contact, and feeling ill, whereas chemotherapy, worse emotional functioning, speech problems and weight loss were significantly associated with the course of depression. Regarding factors assessed at 6-months, chemotherapy, worse cognitive and social functioning, insomnia, swallowing problems and trouble with social eating were associated with the course of anxiety. Nausea/vomiting, dyspnea, coughing, and feeling ill were associated with the course of depression (p-values < 0.05). DISCUSSION: Factors associated with a worse course of anxiety and depression are younger age, treatment with chemotherapy, worse HRQOL and higher symptom burden.
OBJECTIVES: To identify sociodemographic and clinical factors, health-related quality of life (HRQOL) and head and neck cancer (HNC) symptoms associated with the course of symptoms of anxiety and depression from pretreatment to 24-month follow-up among HNCpatients after (chemo)radiation. MATERIALS AND METHODS:Patients (n = 345) completed questionnaires on anxiety and depression (HADS), HRQOL and symptoms (EORTC QLQ-C30/QLQ-H&N35) before treatment, and 6-weeks,3-,6-12-,18-, and 24-months after treatment. Mixed model analyses were used to investigate the course of anxiety and depression from pretreatment to 24-months in relation to factors assessed at baseline, and the course of anxiety and depression from 6- to 24-months, in relation to factors assessed at 6-months. RESULTS: Increased risk for anxiety (HADS-anxiety > 7) was 28.7% among patients before treatment, which declined to 10.0% at 24-months. Increased risk for depression (HADS-depression > 7) was 15.1% before treatment, 18.2% at 3-months, 7.2% at 12-months and 16.0% at 24-months. Factors assessed at baseline which were significantly associated with the course of anxiety were age, pain, problems with social contact, and feeling ill, whereas chemotherapy, worse emotional functioning, speech problems and weight loss were significantly associated with the course of depression. Regarding factors assessed at 6-months, chemotherapy, worse cognitive and social functioning, insomnia, swallowing problems and trouble with social eating were associated with the course of anxiety. Nausea/vomiting, dyspnea, coughing, and feeling ill were associated with the course of depression (p-values < 0.05). DISCUSSION: Factors associated with a worse course of anxiety and depression are younger age, treatment with chemotherapy, worse HRQOL and higher symptom burden.
Authors: John M Hoyle; Tanya A Correya; Kelly Kenzik; Liton Francisco; Sharon A Spencer; Christopher D Willey; James A Bonner; James W Snider; Drexell Hunter Boggs; William R Carroll; Smita Bhatia; Andrew M McDonald Journal: Head Neck Date: 2022-01-25 Impact factor: 3.147
Authors: Florie E van Beek; Femke Jansen; Rob J Baatenburg de Jong; Johannes A Langendijk; C René Leemans; Johannes H Smit; Robert P Takes; Chris H J Terhaard; José A E Custers; Judith B Prins; Birgit I Lissenberg-Witte; Irma M Verdonck-de Leeuw Journal: Curr Oncol Date: 2022-04-30 Impact factor: 3.109